Most Read

Leveraging Neurimmune’s reverse translational medicine (RTM) technology platform, the alliance will create antibody therapies against new treatment targets in the neurodegenerative disease field. RTM technology platform is a

The latest move follows the receipt of European Commission (EC) approval for the drug in December last year. Cibinqo, the oral small molecule drug, selectively hinders Janus kinase

As part of the collaboration, the companies will use Prellis Biologics’ externalised human immune system (EXIS) which is based on human lymph node organoids (LNO). The human antibody

The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a

The laboratory of Steven Rosenberg, chief of surgery at the NCI, discovered these TCRs. NCI is an institute of the National Institutes of Health (NIH). Neogene’s neoantigen TCR

As part of the collaboration, the company will use its Deep Learning-Enabled Drug Creation and Bionic Protein non-standard amino acid technologies to create enzymes to meet Merck’s biomanufacturing

A selective JAK inhibitor, Rinvoq is currently being analysed in various immune-mediated inflammatory diseases. Both the submissions are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical

The partnership aims to develop new drugs with predictable manufacturing and clinical behaviour. Under the deal, Amgen will make an upfront investment of $50m for the first five

The latest move follows a collaboration and license agreement signed by the companies in November last year. Sold in the US under the brand name Nurtec ODT, rimegepant